Vindesine sulfate | CAS# 59917-39-4 (sulfate) | antineoplastic activity against CANCER

MedKoo Cat#: 413555 | Name: Vindesine sulfate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vindesine sulfate is a vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).

Chemical Structure

Vindesine sulfate

CAS#59917-39-4 (sulfate)

Theoretical Analysis

MedKoo Cat#: 413555

Name: Vindesine sulfate

CAS#: 59917-39-4 (sulfate)

Chemical Formula: C43H57N5O11S

Exact Mass: 851.3775

Molecular Weight: 852.01

Elemental Analysis: C, 60.62; H, 6.74; N, 8.22; O, 20.66; S, 3.76

Price and Availability

Size	Price	Availability	Quantity

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

59917-39-4 (sulfate) 53643-48-4 (free base)

Synonym

Vindesine sulfate; LY099094; LY-099094; LY 099094

IUPAC/Chemical Name

methyl (5S,7R,9S)-9-((3aR,3a1R,4R,5S,5aR,10bR)-5-carbamoyl-3a-ethyl-4,5-dihydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazol-9-yl)-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methano[1]azacycloundecino[5,4-b]indole-9-carboxylate sulfate

InChi Key

COFJBSXICYYSKG-OAUVCNBTSA-N

InChi Code

InChI=1S/C43H55N5O7.H2O4S/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50;1-5(2,3)4/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50);(H2,1,2,3,4)/t25-,34-,35+,36+,39-,40+,41+,42-,43-;/m0./s1

SMILES Code

CC[C@@]1(C[C@@H]2CN(C1)CCc(c([C@@](C(OC)=O)(c3c(OC)cc(N([C@H]4[C@]([C@@H]([C@@]5(C=CCN6CC[C@]74[C@H]56)CC)O)(C(N)=O)O)C)c7c3)C2)[nH]8)c9c8cccc9)O.OS(=O)(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 852.01 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Cersosimo RJ, Bromer R, Licciardello JT, Hong WK. Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new vinca alkaloid. Pharmacotherapy. 1983 Sep-Oct;3(5):259-74. doi: 10.1002/j.1875-9114.1983.tb03269.x. PMID: 6359081. 2: Gökbuget N, Hoelzer D. Vindesine in the treatment of leukaemia. Leuk Lymphoma. 1997 Aug;26(5-6):497-506. doi: 10.3109/10428199709050886. PMID: 9389357. 3: Cohen MR. Vindesine tragedy. Nursing. 2009 Mar;39(3):12. doi: 10.1097/01.NURSE.0000347050.21740.8c. PMID: 19247102. 4: Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, Sawa T, Yokota S, Seto T, Imamura F, Saka H, Iwamoto Y, Semba H, Chiba Y, Uejima H, Fukuoka M. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol. 2010 Aug 10;28(23):3739-45. doi: 10.1200/JCO.2009.24.5050. Epub 2010 Jul 12. PMID: 20625120. 5: Huang C, Xia F, Xue L, Liu L, Bian Y, Jin Z, Miao L. Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3. Cancer Chemother Pharmacol. 2020 Feb;85(2):433-441. doi: 10.1007/s00280-019-03972-6. Epub 2019 Nov 5. PMID: 31691080. 6: Li J, Yao C, Xu Y, Ping P, Yin H, Sun Y. In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag. J Clin Pharm Ther. 2019 Dec;44(6):875-882. doi: 10.1111/jcpt.13007. Epub 2019 Sep 17. PMID: 31529525. 7: Gaukroger JM, Wilson L, MacKie R. Cytotoxicity of etretinate and vindesine. Br J Cancer. 1985 Sep;52(3):369-75. doi: 10.1038/bjc.1985.203. PMID: 4041363; PMCID: PMC1977201. 8: Einhorn LH, Loehrer PJ, Williams SD, Meyers S, Gabrys T, Nattan SR, Woodburn R, Drasga R, Songer J, Fisher W, et al. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol. 1986 Jul;4(7):1037-43. doi: 10.1200/JCO.1986.4.7.1037. PMID: 3088219. 9: Sørensen JB, Hansen HH. Is there a role for vindesine in the treatment of non-small cell lung cancer? Invest New Drugs. 1993 May-Aug;11(2-3):103-33. doi: 10.1007/BF00874146. PMID: 8262725. 10: Al-Quteimat OM. Vincristine Shortage: What Other Options We Have? Am J Clin Oncol. 2020 Feb;43(2):146-147. doi: 10.1097/COC.0000000000000648. PMID: 31977507.